Adipocytokines, Hepatic and Inflammatory Biomarkers and Incidence of Type 2 Diabetes. The CoLaus Study
Open Access
- 12 December 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (12) , e51768
Abstract
There is contradictory information regarding the prognostic importance of adipocytokines, hepatic and inflammatory biomarkers on the incidence of type 2 diabetes. The objective was to assess the prognostic relevance of adipocytokine and inflammatory markers (C-reactive protein – CRP; interleukin-1beta – IL-1β; interleukin-6– IL-6; tumour necrosis factor-α – TNF-α; leptin and adiponectin) and gamma-glutamyl transpeptidase (γGT) on the incidence of type 2 diabetes. Prospective, population-based study including 3,842 non-diabetic participants (43.3% men, age range 35 to 75 years), followed for an average of 5.5 years (2003–2008). The endpoint was the occurrence of type 2 diabetes. 208 participants (5.4%, 66 women) developed type 2 diabetes during follow-up. On univariate analysis, participants who developed type 2 diabetes had significantly higher baseline levels of IL-6, CRP, leptin and γGT, and lower levels of adiponectin than participants who remained free of type 2 diabetes. After adjusting for a validated type 2 diabetes risk score, only the associations with adiponectin: Odds Ratio and (95% confidence interval): 0.97 (0.64–1.47), 0.84 (0.55–1.30) and 0.64 (0.40–1.03) for the second, third and forth gender-specific quartiles respectively, remained significant (P-value for trend = 0.05). Adding each marker to a validated type 2 diabetes risk score (including age, family history of type 2 diabetes, height, waist circumference, resting heart rate, presence of hypertension, HDL cholesterol, triglycerides, fasting glucose and serum uric acid) did not improve the area under the ROC or the net reclassification index; similar findings were obtained when the markers were combined, when the markers were used as continuous (log-transformed) variables or when gender-specific quartiles were used. Decreased adiponectin levels are associated with an increased risk for incident type 2 diabetes, but they seem to add little information regarding the risk of developing type 2 diabetes to a validated risk score.Keywords
This publication has 56 references indexed in Scilit:
- Evaluation of the combined use of adiponectin and C-reactive protein levels as biomarkers for predicting the deterioration in glycaemia after a median of 5.4 yearsDiabetologia, 2011
- Evaluating the Incremental Value of New Biomarkers With Integrated Discrimination ImprovementAmerican Journal of Epidemiology, 2011
- Levels and Determinants of Inflammatory Biomarkers in a Swiss Population-Based Sample (CoLaus Study)PLOS ONE, 2011
- Immunological and Cardiometabolic Risk Factors in the Prediction of Type 2 Diabetes and Coronary Events: MONICA/KORA Augsburg Case-Cohort StudyPLOS ONE, 2011
- Risk Assessment Tools for Identifying Individuals at Risk of Developing Type 2 DiabetesEpidemiologic Reviews, 2011
- Assessment of Clinical Validity of a Breast Cancer Risk Model Combining Genetic and Clinical InformationJNCI: Journal of the National Cancer Institute, 2010
- Thirty-One Novel Biomarkers as Predictors for Clinically Incident DiabetesPLOS ONE, 2010
- Criteria for Evaluation of Novel Markers of Cardiovascular RiskCirculation, 2009
- Low Serum Adiponectin Predicts 10-Year Risk of Type 2 Diabetes and HbA1c Independently of Obesity, Lipids, and Inflammation: Whitehall II StudyHormone and Metabolic Research, 2009
- The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndromeBMC Cardiovascular Disorders, 2008